Cargando…

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD

PURPOSE OF REVIEW: Apolipoprotein C-III (apoC-III) is known to inhibit lipoprotein lipase (LPL) and function as an important regulator of triglyceride metabolism. In addition, apoC-III has also more recently been identified as an important risk factor for cardiovascular disease. This review summariz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taskinen, Marja-Riitta, Packard, Chris J., Borén, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Nonstatin Drugs (R. Carmena, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527792/ https://www.ncbi.nlm.nih.gov/pubmed/31111320 http://dx.doi.org/10.1007/s11883-019-0791-9

Ejemplares similares

Current Role of Lipoprotein Apheresis
por: Thompson, Gilbert, et al.
Publicado: (2019)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2020)

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
por: Borén, Jan, et al.
Publicado: (2020)

Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
por: Fruchart, Jean-Charles, et al.
Publicado: (2020)

Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations
por: Taskinen, Marja-Riitta, et al.
Publicado: (2022)

Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease
por: Packard, Chris J.
Publicado: (2022)

Causes and Consequences of Hypertriglyceridemia
por: Packard, Chris J., et al.
Publicado: (2020)

Dietary Fructose and the Metabolic Syndrome
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia
por: Stefanutti, Claudia
Publicado: (2020)

The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia
por: Penson, Peter E., et al.
Publicado: (2020)

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
por: Pirillo, Angela, et al.
Publicado: (2021)

RNA Silencing in the Management of Dyslipidemias
por: Henney, Neil C., et al.
Publicado: (2021)

Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)
por: D’Erasmo, Laura, et al.
Publicado: (2021)

Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
por: Cicero, Arrigo F. G., et al.
Publicado: (2021)

Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?
por: Parhofer, Klaus G.
Publicado: (2021)

Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins
por: Visser, Jolien, et al.
Publicado: (2022)

Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?
por: Taskinen, Marja-Riitta, et al.
Publicado: (2016)

Sex differences in HDL ApoC-III in American Indian youth
por: Blackett, Piers R, et al.
Publicado: (2012)

ApoC-III is a novel inducer of calcification in human aortic valves
por: Schlotter, Florian, et al.
Publicado: (2021)

Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part II: Novel Niacin Mimetics
por: Goel, Harsh, et al.
Publicado: (2016)

Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges
por: Elbers, L.P.B., et al.
Publicado: (2016)

Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part I: Alternative Niacin Regimens
por: Dunbar, Richard L., et al.
Publicado: (2016)

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase
por: Bilen, Ozlem, et al.
Publicado: (2016)

Antioxidants in the Fight Against Atherosclerosis: Is This a Dead End?
por: Toledo-Ibelles, Paola, et al.
Publicado: (2018)

ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance
por: Ramms, Bastian, et al.
Publicado: (2019)

New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
por: Kim, Ji Yoon, et al.
Publicado: (2023)

AAV-Mediated ApoC2 Gene Therapy: Reversal of Severe Hypertriglyceridemia and Rescue of Neonatal Death in ApoC2-Deficient Hamsters
por: Yang, Chun, et al.
Publicado: (2020)

Ethnic differences in ApoC-III concentration and the risk of cardiovascular disease: No evidence for the cardioprotective role of rare/loss of function APOC3 variants in non-Europeans
por: Rout, Madhusmita, et al.
Publicado: (2022)

Interventional hepatic apoC-III knockdown improves atherosclerotic plaque stability and remodeling by triglyceride lowering
por: Ramms, Bastian, et al.
Publicado: (2022)

Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study
por: Björnson, Elias, et al.
Publicado: (2023)

Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy
por: Taskinen, Marja-Riitta, et al.
Publicado: (2023)

Associations among Race/Ethnicity, ApoC-III Genotypes, and Lipids in HIV-1-Infected Individuals on Antiretroviral Therapy
por: Foulkes, Andrea S, et al.
Publicado: (2006)

ApoE Polymorphism Is Associated With C-Reactive Protein in Low-HDL Family Members and in Normolipidemic Subjects
por: Kahri, Juhani, et al.
Publicado: (2006)

ApoC3 is expressed in oocytes and increased expression is associated with PCOS progression
por: Zhou, Jiahe, et al.
Publicado: (2023)

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
por: Ballantyne, Christie M, et al.
Publicado: (2019)

Investigation of human apoB48 metabolism using a new, integrated non‐steady‐state model of apoB48 and apoB100 kinetics
por: Björnson, E., et al.
Publicado: (2019)

Lp(a): a New Pathway to Target?
por: Nurmohamed, Nick S., et al.
Publicado: (2022)

Bempedoic Acid: for Whom and When
por: Ruscica, Massimiliano, et al.
Publicado: (2022)

PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2022)

Inclisiran: How Widely and When Should We Use It?
por: Pirillo, Angela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cgefl9lskd4v6f11fdr9836a8h